Saltar al contenido
Merck

CaMKII-δ9 Induces Cardiomyocyte Death to Promote Cardiomyopathy and Heart Failure.

Frontiers in cardiovascular medicine (2022-02-08)
Mao Zhang, Junxia Zhang, Wenjia Zhang, Qingmei Hu, Li Jin, Peng Xie, Wen Zheng, Haibao Shang, Yan Zhang
RESUMEN

Heart failure is a syndrome in which the heart cannot pump enough blood to meet the body's needs, resulting from impaired ventricular filling or ejection of blood. Heart failure is still a global public health problem and remains a substantial unmet medical need. Therefore, it is crucial to identify new therapeutic targets for heart failure. Ca2+/calmodulin-dependent kinase II (CaMKII) is a serine/threonine protein kinase that modulates various cardiac diseases. CaMKII-δ9 is the most abundant CaMKII-δ splice variant in the human heart and acts as a central mediator of DNA damage and cell death in cardiomyocytes. Here, we proved that CaMKII-δ9 mediated cardiomyocyte death promotes cardiomyopathy and heart failure. However, CaMKII-δ9 did not directly regulate cardiac hypertrophy. Furthermore, we also showed that CaMKII-δ9 induced cell death in adult cardiomyocytes through impairing the UBE2T/DNA repair signaling. Finally, we demonstrated no gender difference in the expression of CaMKII-δ9 in the hearts, together with its related cardiac pathology. These findings deepen our understanding of the role of CaMKII-δ9 in cardiac pathology and provide new insights into the mechanisms and therapy of heart failure.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Roche
Kit de detección de muerte celular in situ, fluoresceína, sufficient for ≤50 tests, suitable for detection
Sigma-Aldrich
Anticuerpo anti-fosfo-histona H2A.X (Ser139), clon JBW301, clone JBW301, Upstate®, from mouse
Sigma-Aldrich
Z-VAD-FMK, solid